Cytokinetics CYTK
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Cytokinetics (CYTK) Business Model and Operations Summary
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Key Insights
Cytokinetics (CYTK) Core Market Data and Business Metrics
Latest Closing Price
$37.5Market Cap
$4.49 BillionPrice-Earnings Ratio
-6.97Total Outstanding Shares
114.66 Million SharesTotal Employees
564Dividend
No dividendIPO Date
April 29, 2004SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
350 Oyster Point Boulevard, South San Francisco, CA, 94080
Historical Stock Splits
If you bought 6 shares of CYTK before June 25, 2013, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| June 25, 2013 | 1-for-6 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-52.80 Million |
| Exchange Gains/Losses | $-103,000 |
| Net Cash Flow From Financing Activities, Continuing | $1.10 Billion |
| Net Cash Flow From Financing Activities | $1.10 Billion |
| Net Cash Flow From Investing Activities | $-745.37 Million |
| Net Cash Flow From Operating Activities, Continuing | $-404.36 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-415.39 Million |
| Income/Loss From Continuing Operations After Tax | $-576.40 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $-576.40 Million |
| Operating Expenses | $527.85 Million |
| Interest Expense, Operating | $35.93 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $6.26 Million |
| Comprehensive Income/Loss Attributable To Parent | $-570.14 Million |
| Comprehensive Income/Loss | $-570.14 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $417.46 Million |
| Other Non-current Assets | $353.24 Million |
| Wages | $27.88 Million |
| Liabilities And Equity | $1.44 Billion |
| Current Liabilities | $109.81 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||